-
Something wrong with this record ?
Diagnostics of the cardio-toxic effects of oncology therapies
Roman Podoba, Anton Lacko, Ján Straka, Lukáš Zachar
Language English Country Czech Republic
- MeSH
- 3-Iodobenzylguanidine MeSH
- Anthracyclines classification adverse effects MeSH
- Bevacizumab adverse effects MeSH
- Biological Therapy adverse effects MeSH
- Molecular Targeted Therapy classification adverse effects MeSH
- Echocardiography methods MeSH
- Electrocardiography methods MeSH
- Fluorouracil adverse effects MeSH
- Tomography, Emission-Computed, Single-Photon methods MeSH
- Cardiotoxicity * diagnosis etiology classification MeSH
- Humans MeSH
- Magnetic Resonance Imaging MeSH
- Myocardium pathology MeSH
- Neoplasms drug therapy complications MeSH
- Heart Diseases diagnostic imaging diagnosis chemically induced MeSH
- Antineoplastic Agents * classification adverse effects MeSH
- Radionuclide Ventriculography methods MeSH
- Risk Factors MeSH
- Sunitinib adverse effects MeSH
- Trastuzumab adverse effects MeSH
- Check Tag
- Humans MeSH
Despite the rising trend of cancer disease incidence more and more patients succeed in their fight with the disease. Innovative drugs bring cures or at least improvements to the patient's quality of life. Extensive application of anticancer therapy however brings about the increase of adverse effects of the therapy. Toxic damage of the myocardium remains one of the severest organ damage types with life-threatening consequences. In the last decade, in addition to the known cardio toxicity of traditional cytostatics, specialists have more and more often been facing cardio toxicity caused by targeted oncology therapies. As myocardium damage is hard to treat when the stage of clinical symptoms is reached, emphasis is laid on the timely diagnosing of this drug-related damage. Diagnostic procedures have been introduced for early detection of risk patients before the therapy has even commenced. Timely diagnosis of myocardium effects in the course of the conservative cancer therapy allows for adjustment of the oncology therapy and lifestyle and timely commencement of treatment of the affected myocardium. Echocardiograph is considered the basic procedure of patient monitoring during cancer therapy. MRI of the myocardium and CT cardiograph are limited by price and availability despite their uncontentious role in oncocardiology. Radionuclide ventriculography is considered the gold standard of assessment of the left ventricle function. It is well reproducible and widely available in oncology centres. Laboratory diagnostics of toxic damage of the myocardium focuses on cardinal troponins and natriuretic peptides. This examination performance in clinical practice is undemanding and its application in oncology practice increases.
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18004570
- 003
- CZ-PrNML
- 005
- 20190311130621.0
- 007
- cr|cn|
- 008
- 180209s2017 xr a fs 000 0|eng||
- 009
- AR
- 024 7_
- $2 doi $a 10.32725/jnss.2017.004
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Podoba, Roman $7 _AN094818 $u Catholic University in Ružomberok, Faculty of Health, Ružomberok, Slovak Republic; Central Military Hospital SNP in Ružomberok, Department of Radiation and Clinical Oncology, Ružomberok, Slovak Republic
- 245 10
- $a Diagnostics of the cardio-toxic effects of oncology therapies / $c Roman Podoba, Anton Lacko, Ján Straka, Lukáš Zachar
- 504 __
- $a Literatura
- 520 9_
- $a Despite the rising trend of cancer disease incidence more and more patients succeed in their fight with the disease. Innovative drugs bring cures or at least improvements to the patient's quality of life. Extensive application of anticancer therapy however brings about the increase of adverse effects of the therapy. Toxic damage of the myocardium remains one of the severest organ damage types with life-threatening consequences. In the last decade, in addition to the known cardio toxicity of traditional cytostatics, specialists have more and more often been facing cardio toxicity caused by targeted oncology therapies. As myocardium damage is hard to treat when the stage of clinical symptoms is reached, emphasis is laid on the timely diagnosing of this drug-related damage. Diagnostic procedures have been introduced for early detection of risk patients before the therapy has even commenced. Timely diagnosis of myocardium effects in the course of the conservative cancer therapy allows for adjustment of the oncology therapy and lifestyle and timely commencement of treatment of the affected myocardium. Echocardiograph is considered the basic procedure of patient monitoring during cancer therapy. MRI of the myocardium and CT cardiograph are limited by price and availability despite their uncontentious role in oncocardiology. Radionuclide ventriculography is considered the gold standard of assessment of the left ventricle function. It is well reproducible and widely available in oncology centres. Laboratory diagnostics of toxic damage of the myocardium focuses on cardinal troponins and natriuretic peptides. This examination performance in clinical practice is undemanding and its application in oncology practice increases.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nemoci srdce $x diagnostické zobrazování $x diagnóza $x chemicky indukované $7 D006331
- 650 _2
- $a nádory $x farmakoterapie $x komplikace $7 D009369
- 650 _2
- $a myokard $x patologie $7 D009206
- 650 12
- $a protinádorové látky $x klasifikace $x škodlivé účinky $7 D000970
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a cílená molekulární terapie $x klasifikace $x škodlivé účinky $7 D058990
- 650 _2
- $a biologická terapie $x škodlivé účinky $7 D001691
- 650 _2
- $a antracykliny $x klasifikace $x škodlivé účinky $7 D018943
- 650 _2
- $a fluoruracil $x škodlivé účinky $7 D005472
- 650 _2
- $a trastuzumab $x škodlivé účinky $7 D000068878
- 650 _2
- $a bevacizumab $x škodlivé účinky $7 D000068258
- 650 _2
- $a sunitinib $x škodlivé účinky $7 D000077210
- 650 _2
- $a elektrokardiografie $x metody $7 D004562
- 650 _2
- $a echokardiografie $x metody $7 D004452
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a jednofotonová emisní výpočetní tomografie $x metody $7 D015899
- 650 _2
- $a radioisotopová ventrikulografie $x metody $7 D015635
- 650 _2
- $a 3-jodobenzylguanidin $7 D019797
- 650 12
- $a kardiotoxicita $x diagnóza $x etiologie $x klasifikace $7 D066126
- 700 1_
- $a Lacko, Anton $7 xx0040455 $u Catholic University in Ružomberok, Faculty of Health, Ružomberok, Slovak Republic; Central Military Hospital SNP in Ružomberok, Department of Nuclear Medicine, Ružomberok, Slovak Republic
- 700 1_
- $a Straka, Ján $7 xx0273698 $u Catholic University in Ružomberok, Faculty of Health, Ružomberok, Slovak Republic; Central Military Hospital SNP in Ružomberok, Department of Nuclear Medicine, Ružomberok, Slovak Republic
- 700 1_
- $a Zachar, Lukáš $7 xx0304190 $u Catholic University in Ružomberok, Faculty of Health, Ružomberok, Slovak Republic
- 773 0_
- $t Journal of nursing, social studies and public health $x 1804-1868 $g Roč. 8, č. 1-2 (2017), s. 39-48 $w MED00171246
- 856 41
- $u https://jnss.zsf.jcu.cz/artkey/jns-201701-0004_diagnostics-of-the-cardio-toxic-effects-of-oncology-therapies.php $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 4268 $c 673 $y 4 $z 0
- 990 __
- $a 20180209105529 $b ABA008
- 991 __
- $a 20190311130942 $b ABA008
- 999 __
- $a ok $b bmc $g 1274829 $s 1001291
- BAS __
- $a 3 $a 4
- BMC __
- $a 2017 $b 8 $c 1-2 $d 39-48 $i 1804-1868 $m Journal of Nursing, Social Studies and Public Health $x MED00171246
- LZP __
- $c NLK185 $d 20190311 $a NLK 2018-01/dk
